These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9882925)

  • 61. Dose optimization of recombinant factor VIIa in the treatment of acute bleeding in haemophilia-associated inhibitors.
    Seremetis S
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S29-30. PubMed ID: 14567532
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Health economic review of recombinant activated factor VII for treatment of bleeding episodes in hemophilia patients with inhibitors.
    Stephens JM; Joshi AV; Sumner M; Botteman MF
    Expert Opin Pharmacother; 2007 Jun; 8(8):1127-36. PubMed ID: 17516876
    [TBL] [Abstract][Full Text] [Related]  

  • 63. American experience with home use of NovoSeven: recombinant factor VIIa in hemophiliacs with inhibitors.
    Shapiro AD
    Haemostasis; 1996; 26 Suppl 1():143-9. PubMed ID: 8904190
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: a multicentre study.
    Hay CR; Negrier C; Ludlam CA
    Thromb Haemost; 1997 Dec; 78(6):1463-7. PubMed ID: 9423795
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The use of recombinant activated factor VII in patients with acquired haemophilia.
    Tiede A; Amano K; Ma A; Arkhammar P; El Fegoun SB; Rosholm A; Seremetis S; Baudo F
    Blood Rev; 2015 Jun; 29 Suppl 1():S19-25. PubMed ID: 26073365
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Surgery in haemophilia patients with inhibitors, with special emphasis on orthopaedics: Madrid experience.
    Rodriguez-Merchan EC; Jimenez-Yuste V; Gomez-Cardero P; Alvarez-Roman M; Martin-Salces M; Rodriguez de la Rua A
    Haemophilia; 2010 May; 16(102):84-8. PubMed ID: 20536990
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
    Abshire TC
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Use of recombinant factor VIIa (NovoSeven) in a haemophilia A patient with inhibitor in Kuwait.
    Kanyike FB; Abdul-Salam SA; Prakash B; Sharhan A; Wahib N; Youssef AH
    Haemophilia; 1999 Jul; 5(4):273-5. PubMed ID: 10469183
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Inhibitor treatment: state of the art.
    Shapiro A
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):26-34. PubMed ID: 11735107
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treatment of acquired factor VIII inhibitor with recombinant activated factor VIIa: data from the Italian registry of acquired hemophilia.
    Baudo F; de Cataldo F; Gaidano G;
    Haematologica; 2004 Jun; 89(6):759-61. PubMed ID: 15194550
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors.
    Santagostino E; Mancuso ME; Rocino A; Mancuso G; Scaraggi F; Mannucci PM
    J Thromb Haemost; 2006 Feb; 4(2):367-71. PubMed ID: 16420567
    [TBL] [Abstract][Full Text] [Related]  

  • 75. NovoSeven in immune tolerance therapy.
    Brackmann HH; Effenberger E; Hess L; Schwaab R; Oldenburg J
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S39-44. PubMed ID: 10850563
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
    Hedner U
    Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
    [No Abstract]   [Full Text] [Related]  

  • 77. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors.
    Hay JW; Chaugule SC; Young G
    Haemophilia; 2013 Sep; 19(5):711-9. PubMed ID: 23672765
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis.
    Zhou ZY; Hay JW
    Clin Ther; 2012 Feb; 34(2):434-45. PubMed ID: 22285208
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study.
    Macik BG; Lindley CM; Lusher J; Sawyer WT; Bloom AL; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
    Blood Coagul Fibrinolysis; 1993 Aug; 4(4):521-7. PubMed ID: 8218848
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
    Santagostino E; Escobar M; Ozelo M; Solimeno L; Arkhammar P; Lee HY; Rosu G; Giangrande P
    Blood Rev; 2015 Jun; 29 Suppl 1():S9-18. PubMed ID: 26073369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.